Guhan Pharmaceutical Group Co

Guhan Pharmaceutical Group Co Current Assets

The Current Assets of Guhan Pharmaceutical Group Co (000590.SZ) as of Oct 30, 2026 is 113.45 M CNY. In the previous year, Current Assets was 502.23 M CNY — a change of -77.41% (lower).

Current Assets

113.45 MCNY

YoY

-77.41%

Last updated:

Current Assets of Guhan Pharmaceutical Group Co is 2025 113.45 M CNY. Current Assets of Guhan Pharmaceutical Group Co was 2024 502.23 M CNY. It decreases by -77.41% lower compared to the previous year.

The Guhan Pharmaceutical Group Co Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
459.57 M CNY
Jan 1, 2019
500.56 M CNY
Jan 1, 2020
510.49 M CNY
Jan 1, 2021
559.90 M CNY
Jan 1, 2022
559.40 M CNY
Jan 1, 2023
602.31 M CNY
Jan 1, 2024
502.23 M CNY
Jan 1, 2025
113.45 M CNY
The Guhan Pharmaceutical Group Co Current Assets history
YEARCurrent AssetsYoY
113.45 MCNY-77.41%
502.23 MCNY-16.62%
602.31 MCNY+7.67%
559.40 MCNY-0.09%
559.90 MCNY+9.68%
510.49 MCNY+1.98%
500.56 MCNY+8.92%
459.57 MCNY-11.85%
521.35 MCNY+78.90%
291.42 MCNY+21.24%
240.37 MCNY+2.33%
234.89 MCNY-18.69%
288.88 MCNY-30.62%
416.38 MCNY+81.44%
229.49 MCNY-2.50%
235.37 MCNY+15.46%
203.86 MCNY-27.82%
282.43 MCNY-8.94%
310.15 MCNY-16.11%
369.72 MCNY+0.77%
366.90 MCNY-0.49%
368.72 MCNY-35.49%
571.55 MCNY+54.20%
370.65 MCNY-6.78%
397.61 MCNY-25.17%
531.34 MCNY+9.92%
483.38 MCNY+24.77%
387.41 MCNY+78.26%
217.33 MCNY+101.32%
107.95 MCNY+27.05%
84.97 MCNY—
0.00CNY—
0.00CNY—
0.00CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Guhan Pharmaceutical Group Co Stock analysis

What does Guhan Pharmaceutical Group Co do? Tus-Pharmaceutical Group Co., Ltd. generates revenue through the research and development, production, and sales of Chinese patent medicine and western medicine preparations. The company offers Chinese healthcare products, cold treatment medicines, and anti hyperlipemia medicines, alongside western medicine products such as clindamycin phosphate for injection, lomefloxacin hydrochloride for injection, and levofloxacin lactate for injection. Domestic markets are the primary sales channel for all products. The firm's revenue streams are derived from the sale of these pharmaceutical products to domestic customers. The company focuses on Chinese patent medicine, including healthcare products, cold treatment remedies, and anti hyperlipemia treatments. Western medicine preparations like clindamycin phosphate for injection, lomefloxacin hydrochloride for injection, and levofloxacin lactate for injection form a significant part of its product portfolio. These products are distributed exclusively within China, targeting domestic consumers and healthcare providers. Tus-Pharmaceutical Group Co., Ltd. serves domestic markets with its range of Chinese and western medicines. The company's product lines include Chinese healthcare products, cold treatment medicines, anti hyperlipemia medicines, and specific western medicine injections. Sales are conducted within China, with no mention of international distribution. The firm's revenue is generated through the direct sale of these pharmaceutical products to domestic buyers. Guhan Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guhan Pharmaceutical Group Co stock

Current Assets of Guhan Pharmaceutical Group Co is 113.45 M CNY in 2025.

Current Assets of Guhan Pharmaceutical Group Co changed from 502.23 M CNY to 113.45 M CNY, representing a -77.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Guhan Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Guhan Pharmaceutical Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Guhan Pharmaceutical Group Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Guhan Pharmaceutical Group Co